Innovent Biologics, Inc. (OTCMKTS:IVBXF – Get Free Report) was down 2.2% on Monday . The stock traded as low as $3.91 and last traded at $3.91. Approximately 548 shares were traded during mid-day trading, a decline of 93% from the average daily volume of 7,550 shares. The stock had previously closed at $4.00.
Innovent Biologics Stock Performance
The company has a 50-day moving average of $4.59 and a 200 day moving average of $5.09.
About Innovent Biologics
Innovent Biologics, Inc, a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People's Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor.
Further Reading
- Five stocks we like better than Innovent Biologics
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- How to Calculate Options Profits
- 3 Steel Stocks Soaring After Tariff Announcements
- What is an Earnings Surprise?
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for Innovent Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovent Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
